Abbott Laboratories Long Term Debt 2010-2025 | ABT
Abbott Laboratories long term debt from 2010 to 2025. Long term debt can be defined as the sum of all long term debt fields.
- Abbott Laboratories long term debt for the quarter ending March 31, 2025 was $12.736B, a 1.27% increase year-over-year.
- Abbott Laboratories long term debt for 2024 was $12.625B, a 7.16% decline from 2023.
- Abbott Laboratories long term debt for 2023 was $13.599B, a 6.36% decline from 2022.
- Abbott Laboratories long term debt for 2022 was $14.522B, a 16.04% decline from 2021.
| Abbott Laboratories Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $12,625 |
| 2023 | $13,599 |
| 2022 | $14,522 |
| 2021 | $17,296 |
| 2020 | $18,527 |
| 2019 | $16,661 |
| 2018 | $19,359 |
| 2017 | $27,210 |
| 2016 | $20,681 |
| 2015 | $5,871 |
| 2014 | $3,393 |
| 2013 | $3,388 |
| 2012 | $18,085 |
| 2011 | $12,040 |
| 2010 | $12,524 |
| 2009 | $11,266 |
| Abbott Laboratories Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2025-03-31 | $12,736 |
| 2024-12-31 | $12,625 |
| 2024-09-30 | $12,825 |
| 2024-06-30 | $13,139 |
| 2024-03-31 | $12,576 |
| 2023-12-31 | $13,599 |
| 2023-09-30 | $14,477 |
| 2023-06-30 | $14,562 |
| 2023-03-31 | $14,615 |
| 2022-12-31 | $14,522 |
| 2022-09-30 | $15,297 |
| 2022-06-30 | $16,755 |
| 2022-03-31 | $17,086 |
| 2021-12-31 | $17,296 |
| 2021-09-30 | $17,446 |
| 2021-06-30 | $17,547 |
| 2021-03-31 | $17,489 |
| 2020-12-31 | $18,527 |
| 2020-09-30 | $18,349 |
| 2020-06-30 | $18,184 |
| 2020-03-31 | $16,804 |
| 2019-12-31 | $16,661 |
| 2019-09-30 | $17,639 |
| 2019-06-30 | $18,982 |
| 2019-03-31 | $18,845 |
| 2018-12-31 | $19,359 |
| 2018-09-30 | $19,284 |
| 2018-06-30 | $19,823 |
| 2018-03-31 | $21,154 |
| 2017-12-31 | $27,210 |
| 2017-09-30 | $23,310 |
| 2017-06-30 | $23,810 |
| 2017-03-31 | $23,764 |
| 2016-12-31 | $20,681 |
| 2016-09-30 | $5,975 |
| 2016-06-30 | $6,016 |
| 2016-03-31 | $5,977 |
| 2015-12-31 | $5,871 |
| 2015-09-30 | $5,953 |
| 2015-06-30 | $5,862 |
| 2015-03-31 | $5,931 |
| 2014-12-31 | $3,393 |
| 2014-09-30 | $3,719 |
| 2014-06-30 | $3,403 |
| 2014-03-31 | $3,387 |
| 2013-12-31 | $3,388 |
| 2013-09-30 | $3,403 |
| 2013-06-30 | $3,411 |
| 2013-03-31 | $3,467 |
| 2012-12-31 | $18,085 |
| 2012-09-30 | $12,055 |
| 2012-06-30 | $12,004 |
| 2012-03-31 | $11,862 |
| 2011-12-31 | $12,040 |
| 2011-09-30 | $13,097 |
| 2011-06-30 | $12,628 |
| 2011-03-31 | $12,530 |
| 2010-12-31 | $12,524 |
| 2010-09-30 | $12,911 |
| 2010-06-30 | $12,613 |
| 2010-03-31 | $10,879 |
| 2009-12-31 | $11,266 |
| 2009-09-30 | $11,577 |
| 2009-06-30 | $11,372 |
| 2009-03-31 | $11,676 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $232.616B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $153.611B | 38.46 |
| Stryker (SYK) | United States | $149.817B | 31.33 |
| EssilorLuxottica (ESLOY) | France | $128.259B | 0.00 |
| Medtronic (MDT) | Ireland | $112.441B | 15.94 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.320B | 0.00 |
| Haleon (HLN) | United Kingdom | $45.596B | 26.03 |
| ResMed (RMD) | United States | $37.597B | 28.24 |
| GE HealthCare Technologies (GEHC) | United States | $34.163B | 16.22 |
| Agilent Technologies (A) | United States | $33.875B | 22.08 |
| Terumo (TRUMY) | Japan | $24.770B | 32.17 |
| Koninklijke Philips (PHG) | Netherlands | $22.956B | 16.11 |
| Insulet (PODD) | United States | $21.162B | 83.07 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.315B | 11.76 |
| Baxter (BAX) | United States | $15.236B | 11.38 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.113B | 0.00 |
| Demant (WILYY) | Denmark | $8.971B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.723B | 23.40 |
| Lantheus Holdings (LNTH) | United States | $5.479B | 13.82 |
| Prestige Consumer Healthcare (PBH) | United States | $3.900B | 17.42 |
| Perrigo (PRGO) | Ireland | $3.676B | 9.32 |
| Haemonetics (HAE) | United States | $3.609B | 16.44 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.334B | 27.70 |
| ICU Medical (ICUI) | United States | $3.192B | 23.54 |
| QuidelOrtho (QDEL) | United States | $1.976B | 13.59 |
| LeMaitre Vascular (LMAT) | United States | $1.875B | 41.91 |
| AtriCure (ATRC) | United States | $1.561B | 0.00 |
| Acuren (TIC) | United States | $1.375B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.248B | 12.67 |
| Phibro Animal Health (PAHC) | United States | $1.212B | 15.49 |
| Green Thumb Industries (GTBIF) | United States | $1.163B | 26.16 |
| Neogen (NEOG) | United States | $1.081B | 13.83 |
| BioLife Solutions (BLFS) | United States | $1.036B | 0.00 |
| InMode (INMD) | Israel | $0.954B | 9.62 |
| Kestra Medical Technologies (KMTS) | United States | $0.757B | 0.00 |
| Owens & Minor (OMI) | United States | $0.669B | 5.55 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.662B | 0.00 |
| CeriBell (CBLL) | United States | $0.622B | 0.00 |
| Evolus (EOLS) | United States | $0.589B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.553B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.507B | 0.00 |
| Valneva SE (VALN) | France | $0.488B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.452B | 0.00 |
| Surmodics (SRDX) | United States | $0.424B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.360B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.344B | 12.67 |
| SNDL (SNDL) | Canada | $0.326B | 0.00 |
| Quanterix (QTRX) | United States | $0.315B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.284B | 0.00 |
| Cerus (CERS) | United States | $0.277B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.272B | 22.90 |
| ZimVie (ZIMV) | United States | $0.263B | 11.94 |
| Sanara MedTech (SMTI) | United States | $0.259B | 0.00 |
| Brainsway (BWAY) | Israel | $0.253B | 66.85 |
| Aurora Cannabis (ACB) | Canada | $0.249B | 73.83 |
| Cresco Labs (CRLBF) | United States | $0.247B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.228B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.221B | 0.00 |
| Biote (BTMD) | United States | $0.218B | 6.14 |
| TriSalus Life Sciences (TLSI) | United States | $0.188B | 0.00 |
| High Tide (HITI) | Canada | $0.188B | 0.00 |
| Organigram Global (OGI) | Canada | $0.186B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.186B | 15.13 |
| Omeros (OMER) | United States | $0.180B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.173B | 0.00 |
| Exagen (XGN) | United States | $0.148B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.147B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.129B | 15.90 |
| Apyx Medical (APYX) | United States | $0.098B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 12.37 |
| Jin Medical (ZJYL) | China | $0.090B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.088B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.088B | 0.00 |
| MacroGenics (MGNX) | United States | $0.086B | 0.00 |
| Veru (VERU) | United States | $0.086B | 0.00 |
| Zynex (ZYXI) | United States | $0.076B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.075B | 0.00 |
| Agape ATP (ATPC) | $0.070B | 0.00 | |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.064B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.062B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 58.29 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| Safety Shot (SHOT) | United States | $0.038B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 13.10 |
| Rockwell Medical (RMTI) | United States | $0.027B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.019B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.012B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |